前收市價 | 18.20 |
開市 | 18.20 |
買盤 | 18.24 x 100 |
賣出價 | 18.31 x 100 |
今日波幅 | 18.05 - 18.42 |
52 週波幅 | 17.56 - 33.99 |
成交量 | |
平均成交量 | 1,870,432 |
市值 | 3.009B |
Beta 值 (5 年,每月) | 0.40 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -0.37 |
業績公佈日 | 2024年5月06日 - 2024年5月10日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 29.54 |
Recent trends in the stock market have seen a shift in investor interest from tech giants, known as the Magnificent 7, towards pharmaceutical companies, particularly those involved in weight-loss drugs. But, it’s important to identify which pharma stocks to sell before they plummet, as not all will benefit equally from the hype. As a result, pharmaceutical companies like Eli Lilly (NYSE:LLY), Pfizer (NYSE:PFE) and Novo Nordisk (NYSE:NVO) are attracting retail investors’ attention given their por
Acadia stock crashed Tuesday after an outsized placebo effect torpedoed the company's efforts to expand Nuplazid to schizophrenia patients.
Acadia Pharmaceuticals said on Monday it does not plan to conduct further clinical trials of its antipsychotic drug, pimavanserin, after it failed to improve negative symptoms of schizophrenia in a late-stage study. The decision comes after two failed attempts to secure regulatory approval for the expanded use of pimavanserin in the treatment of psychosis related to dementia and Alzheimer's disease in 2021 and 2022, respectively. In the current study that involved 454 adult patients, pimavanserin did not outperform a placebo in reducing negative symptoms of schizophrenia, including poor socialization and lack of motivation, Acadia said.